Mitsubishi UFJ Asset Management Co. Ltd. Has $6.41 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 25.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 75,472 shares of the company's stock after acquiring an additional 15,200 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.06% of Vaxcyte worth $6,405,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. CIBC Asset Management Inc boosted its stake in Vaxcyte by 5.5% during the 4th quarter. CIBC Asset Management Inc now owns 3,307 shares of the company's stock valued at $271,000 after purchasing an additional 171 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after buying an additional 260 shares in the last quarter. Catalyst Funds Management Pty Ltd grew its holdings in Vaxcyte by 1.7% during the fourth quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after acquiring an additional 300 shares during the period. Whipplewood Advisors LLC bought a new stake in Vaxcyte in the fourth quarter worth about $28,000. Finally, Blue Trust Inc. lifted its holdings in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after acquiring an additional 371 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

PCVX has been the topic of several recent research reports. Guggenheim reaffirmed a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Needham & Company LLC decreased their price target on shares of Vaxcyte from $140.00 to $90.00 and set a "buy" rating on the stock in a research report on Tuesday. Bank of America cut their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday. The Goldman Sachs Group decreased their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday. Finally, Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Stock Performance

Shares of PCVX stock traded up $1.04 on Friday, reaching $31.60. 5,690,652 shares of the company's stock traded hands, compared to its average volume of 1,119,961. The company has a market capitalization of $4.07 billion, a P/E ratio of -6.87 and a beta of 1.26. Vaxcyte, Inc. has a 12-month low of $29.57 and a 12-month high of $121.06. The business's 50 day moving average price is $74.59 and its two-hundred day moving average price is $89.66.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. Research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now owns 7,175 shares in the company, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total value of $692,080.00. Following the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,250 shares of company stock worth $3,170,738. 3.10% of the stock is currently owned by company insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.